Advertisement
Advertisement
IBIO
iBio, Inc. Common Stock
2.41
USDSponsored
+0.26
+12.23%
Feb 06, 15:59 UTC -5
Closed
After-Market
2.44
+0.03
+1.12%
IBIO Earnings Reports
Positive Surprise Ratio
IBIO beat 7 of 17 last estimates.
41%
Next Report
Next Week
Date of Next Report
Feb 09, 2026
Estimate for Q2 26 (Revenue/ EPS)
$34.00K
/-$0.08
Implied change from Q1 26 (Revenue/ EPS)
-66.00%
/-27.27%
Implied change from Q2 25 (Revenue/ EPS)
-83.00%
/-83.33%
iBio, Inc. Common Stock earnings per share and revenue
On Nov 12, 2025, IBIO reported earnings of -0.11 USD per share (EPS) for Q1 26, missing the estimate of -0.10 USD, resulting in a -5.16% surprise. Revenue reached 100.00 thousand, compared to an expected 25.50 thousand, with a 292.16% difference. The market reacted with a -8.00% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 6 analysts forecast an EPS of -0.08 USD, with revenue projected to reach 34.00 thousand USD, implying an decrease of -27.27% EPS, and decrease of -66.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Amgen Inc
Report Date
Feb 03, 2026 For Q4 25
Estimate
$4.82
Actual
$5.29
Surprise
+9.56%
Bristol-Myers Squibb Co.
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.12
Actual
$1.26
Surprise
+11.88%
GSK plc - ADR
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.23
Actual
$0.49
Surprise
+111.36%
Biogen Inc. Common Stock
Report Date
Feb 06, 2026 For Q4 25
Estimate
$1.62
Actual
$1.99
Surprise
+22.39%
Illumina Inc
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.24
Actual
$1.35
Surprise
+8.01%
QIAGEN N.V.
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.64
Actual
$0.62
Surprise
-3.32%
Arrowhead Research Corporation
Report Date
Feb 05, 2026 For Q1 26
Estimate
$0.25
Actual
$0.22
Surprise
-14.76%
Bio-Techne Corp.
Report Date
Feb 04, 2026 For Q2 26
Estimate
$0.44
Actual
$0.46
Surprise
+3.95%
Immunovant, Inc. Common Stock
Report Date
Feb 06, 2026 For Q3 26
Estimate
-$0.72
Actual
-$0.61
Surprise
+16.27%
Adaptive Biotechnologies Corporation Common Stock
Report Date
Feb 05, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.09
Surprise
+51.33%
FAQ
What were iBio, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, iBio, Inc. Common Stock reported EPS of -$0.11, missing estimates by -5.16%, and revenue of $100.00K, 292.16% above expectations.
How did the market react to iBio, Inc. Common Stock's Q1 2026 earnings?
The stock price moved down -8%, changed from $1.25 before the earnings release to $1.15 the day after.
When is iBio, Inc. Common Stock expected to report next?
The next earning report is scheduled for Feb 09, 2026.
What are the forecasts for iBio, Inc. Common Stock's next earnings report?
Based on 6
analysts, iBio, Inc. Common Stock is expected to report EPS of -$0.08 and revenue of $34.00K for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement